|
Approaches and future prospects for treating HER2-positive breast cancer
|
|
| Author:
|
VIJAY NATH, RAVIKANT GUPTA, SUDHA VENGURLEKAR, SACHIN KUMAR JAIN
|
| Abstract:
|
The most prevalent cancer among females and the main cause of fatalities is breast cancer. About 20% of breast cancer have HER2 overexpression, which is linked to a poor prognosis and a shortened life expectancy. Breast cancer develops when breast cells start to grow and divide abnormally, creating a tumour that may expand to other body parts by encroaching on adjacent tissues through the lymphatic system or bloodstreamTrastuzumab, a monoclonal antibody, is the treatment of choice which targets the HER2 receptor. But one-third of the patients don't get better with treatment.There are other HER2-targeted strategies known in response to the enhanced resistance rate. The remarkable clinical efficacy shown in several trials involving CAR-M and CAR-NK therapies, vaccines, monoclonal antibodies like pertuzumab, tyrosine kinase inhibitors like lapatinib and tucatinib, and antibody-drug conjugates like trastuzumab-emtansine (T-DM1) and trastuzumab-deruxtecan.
|
| Keyword:
|
HER2 overexpression, prognosis, resistance, efficacy, receptor,breast cancer
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2025.17.01.006
|
| Download:
|
Request For Article
|
|
|